Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

Core Viewpoint - Humacyte, Inc. has announced a public offering of 25 million shares at a price of $2.00 per share, aiming to raise approximately$50 million for commercialization and development purposes [1][2]. Group 1: Offering Details - The public offering consists of 25,000,000 shares priced at $2.00 each, with expected gross proceeds of$50 million before expenses [1]. - The offering is expected to close around March 27, 2025, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase an additional 3,750,000 shares at the public offering price [1]. Group 2: Use of Proceeds - Humacyte plans to use the net proceeds from the offering to fund the commercialization of its product SYMVESS™ for vascular trauma, develop product candidates in its pipeline, and for working capital and general corporate purposes [2]. Group 3: Company Background - Humacyte is focused on developing bioengineered human tissues and advanced tissue constructs to improve patient outcomes [5]. - The company’s initial product candidates, acellular tissue engineered vessels (ATEVs), are in late-stage clinical trials for various vascular applications [5]. - ATEV received FDA approval for vascular trauma in December 2024 and has also received RMAT and Fast Track designations for other applications [5].